drugset / Trial / NCT00337532

A Phase II Trial Neoadjuvant Paclitaxel and Cisplatin in Patients With Locally Advanced Head and Neck Cancer

NCT00337532

Phase 2/3 Completed 50 enrolled Bristol-Myers Squibb
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this clinical research study is to learn if a paclitaxel-cisplatin combination regimen given in the neoadjuvant setting is active in locally advanced head and neck cancer. the safety of this treatment will also be studied.

Timeline

Start
2005-05
Primary completion
2007-06
Completion
2007-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cisplatin Other / unclassified 45 mg/m2 Intravenous
Comparator Cisplatin Other / unclassified 60 mg/m2 Intravenous
Comparator Cisplatin Other / unclassified 75 mg/m2 Intravenous
Comparator Paclitaxel Small molecule 105 mg/m2
Comparator Paclitaxel Small molecule 140 mg/m2
Comparator Paclitaxel Small molecule 175 mg/m2

Indications